Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy

American Journal of Nephrology

Volumn 19, Issue 1, 1999, Pages 1-6

  Hebert, Lee A ^a,b   Falkenhain, Michael E ^a   Nahman Jr , N Stanley ^a   Cosio, Fernando G ^a   O'Dorisio, Thomas M ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Angiotensin blockade; Angiotensin inhibition; Diabetic nephropathy

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIET; FEMALE; GLUCOSE BLOOD LEVEL; HEMODYNAMICS; HUMAN; HYPERTROPHY; HYPOTENSION; MALE; ORAL DRUG ADMINISTRATION; PHYSICAL ACTIVITY; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEINURIA;

EID: 0033023519     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000013417     Document Type: Article

References (31)

1. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329:1456-1462.
2. Mulec H, Johnsen SA, Bjorck S: Long-term enalapril treatment in diabetic nephropathy. Kidney Int 1994;45(suppl 45):S141-S144.
3. Laffel LMB, McGill JB, Gans DJ, on behalf of the North American Microalbuminuria Study Group: The beneficial effect of angiotensin-converting-enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. Am J Med 1995;99:497-504.
4. Parving HH, Rossing P, Hommel E, Smidt UM: Angiotensin-converting-enzyme inhibition in diabetic nephropathy: Ten years' experience. Am J Kidney Dis 1995;26:99-107.
5. Manto A, Cotroneo P, Marra G, Magnani P, Tilli P, Greco AV, Ghirlanda G: Effect of intensive treatment on diabetic nephropathy in patients with type I diabetes. Kidney Int 1995; 47:231-235.
6. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S: Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996;50:1641-1650.
7. Lebovitz HE, Wiegmann TB, Cnaan A, Shahinfar S, Sica DA, Broadstone V, Schwartz SL, Mengel MC, Segal R, Versaggi JA, Bolton WK: Renal protective effects of enalapril in hypertensive NIDDM: Role of baseline albuminuria. Kidney Int 1994;45(suppl 45):S150-S155.
8. Ravid M, Savin H, Jutrin I, Bental T, Lang R, Lishner M: Long-term effect of ACE inhibition on development of nephropathy in diabetes mellitus type II. Kidney Int 1994;45(suppl 45): S161-S164.
9. Ritz E, Stefanski A: Diabetic nephropathy in type II diabetes. Am J Kidney Dis 1996;27: 167-194.
10. Ravid M, Lang R, Rachmani R, Lishner M: Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. Arch Intern Med 1996;156:286-289.
11. Breyer JA, Hunsicker LG, Bain RP, Lewis EJ, and the Collaborative Study Group: Angiotensin converting enzyme inhibition in diabetic nephropathy. Kidney Int 1994;45(suppl 45): S156-S160.
12. Kasiske BL, Kalil RSN, Ma JZ, Liao M, Keane WF: Effect of antihypertensive therapy on the kidney in patients with diabetes: A metaregression analysis. Ann Intern Med 1993;118: 129-138.
13. Hebert LA, Bain RP, Verme D, Cattran D, Wittier FC, Tolchin N, Rohde RD, Lewis EJ, for the Collaborative Study Group: Remission of nephrotic range proteinuria in type I diabetes. Kidney Int 1994;46:1688-1693.
14. Brunner HR, Waeber B, Nussberger J, Schaller MD, Gomez JH: Long-term clinical experience with enalapril in essential hypertension. J Hypertens 1983;1(suppl 1):103-107.
15. Nussberger J, Brunner DB, Waeber B, Brunner HR: True versus immunoreactive angiotensin II in human plasma. Hypertension 1985;7 (suppl D):11-17.
16. Nussberger J, Brunner DB, Waeber B, Brunner HR: Specific measurement of angiotensin metabolites and in vitro generated angiotensin II in plasma. Hypertension 1986;6:476-482.
17. Nahman NS Jr, Rothe KL, Falkenhain M, Frazer K, Dacio LE, Madia JD, Leonhart KL, Kronenberger JC, Stauch DA: Angiotensin II induction of fibroncctin biosynthesis in cultured human mesangial cells: Association with CREB transcription factor activation. J Lab Clin Med 1996;127:599-611.
18. Donovan KL, Coles GA, Williams JD: An ELISA for the detection of type IV collagen in human urine: Application to patients with glomerulonephritis. Kidney Int 1994;46:1431-1437.
19. Goodfriend TL, Elliott ME, Catt KJ: Angiotensin receptors and their antagonists. N Engl J Med 1996;334:1649-1654.
20. Ichikawa I: Will angiotensin II receptor antagonists be renoprotective in humans? Kidney 1996;50:684-692.
21. Gansevoort RT, de Zeeuw D, de Jong PE: Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994;45:860-867.
22. Burnier M, Waeber B, Brunner HR: The advantages of angiotensin II antagonism. J Hypertens 1994;12(suppl 2):S7-S15.
23. Hollenberg NK, Fisher NDL: Renal circulation and blockade of the renin-angiotensin system: Is angiotensin-converting enzyme inhibition the last word? Hypertension 1995;26:602-609.
24. Hemmelder MH, de Zeeuw D, Gansevoort RT, de Jong PE: Blood pressure reduction initiates the antiproteinuric effect of ACE inhibition. Kidney Int 1996;49:174-180.
25. Gibbons GH, Pratt RE, Dzau VJ: Vascular smooth muscle cell hypertrophy vs hyperplasia: Autocrine transforming growth factor-β1 expression determines growth responses to angiotensin II. J Clin Invest 1992;90:456-461.
26. Johnson RJ, Alpers CE, Yoshimura A, Lombardi D, Pritzi P, Floege J, Schwartz SM: Renal injury from angiotensin II-mediated hypertension. Hypertension 1992;19:464-474.
27. Wolf G, Ziyadeh FN: The role of angiotensin II in diabetic nephropathy: Emphasis on nonhemodynamic mechanisms. Am J Kidney Dis 1997;29:153-163.
28. Ruiz-Ortega M, Gonzalez S, Seron D, Condom E, Bustos C, Largo R, Gonzalez E, Ortiz A, Egido J: ACE inhibition reduces proteinura, glomerular lesions and extracellular matrix production in a normotensive rat model of immune complex nephritis. Kidney Int 1995;48: 1778-1792.
29. Cornish KG, Joyner WL, Gilmore JP: Direct evidence for the presence of a different converting enzyme in the hamster cheek pouch. Circ Res 1979;44:540-544.
30. Nishimura H, Hoffmann S, Baltatu O, Sugimura K, Ganten D, Urata H: Angiotensin I converting enzyme and chymase in cardiovascular tissues. Kidney Int 1996;49(suppl 55):S18-S23.
31. Azizi M, Guyene TT, Chatellier G, Wargon M, Menard J: Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension 1997;29:634-640.